Eledon Pharmaceuticals Investor Relations Material

Eledon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat autoimmune diseases, organ transplantation, and neurodegenerative disorders. The company’s lead program involves developing treatments that target CD40L, a key immune system pathway involved in immune response regulation. By modulating this pathway, Eledon aims to develop therapies that prevent organ transplant rejection and treat autoimmune conditions without the need for long-term immunosuppression. The company's innovative approach seeks to address significant unmet medical needs in these therapeutic areas. The company is headquartered in Irvine, California, and its shares are listed on the NASDAQ.